Keywords: adnexal mass CA-125 ovarian cancer risk of malignancy index Wales a b s t r a c t Objective: To evaluate the accuracy of the risk of malignancy index (RMI) which combines serum CA-125 levels, ultrasound score, and menopausal state, in discriminating between benign and malignant adnexal masses in the Welsh population. Materials and methods: Two hundred and forty-seven women with pelvic masses discussed consecutively at the South West Wales Gynaecological Oncology multidisciplinary meeting between January 2010 and June 2011 were included in this retrospective study. The main outcomes were surgical and pathological findings. Results: The sensitivity and specificity of CA-125 at 35kU/L were 76% and 67%, respectively. CA-125 was found to be a relevant predictor of malignancy but the area under the receiver operating characteristic curve for each of the risk of malignancy indices was greater than the area for the CA-125 serum levels alone. Each of the RMIs has a different optimal threshold, however using a threshold of 200, RMI 1 had a sensitivity of 66% and a specificity of 91%; RMI 2 had a sensitivity of 74% and a specificity of 79%; and RMI 3 had a sensitivity of 68% and a specificity of 85%. Conclusion: This is the first study in Wales to evaluate the RMI in triaging women with pelvic masses. Overall, RMI 1 and RMI 2 are better malignancy predictors than RMI 3. It would be recommended that RMI 1 and RMI 2 be compared in a head-to-head prospective study, although we suspect that RMI 1 is likely to be the overall best malignancy predictor.
Introduction
Ovarian cancer is a common gynaecological malignancy with a high mortality. In 2008, the disease was diagnosed in approximately 225,000 women worldwide, accounting for approximately 4% of all cancers diagnosed in women with corresponding 140,000 deaths [1] . In Wales, 373 women received a diagnosis of ovarian cancer in 2007, increasing by more than 5% in 2008 to 392 [2] . Ovarian cancer is more common in older women, with the highest incidence in those aged 75e79 years. [2] . Despite of advances in chemotherapy, ovarian cancer remains a lethal disease. This is because the disease is usually diagnosed at an advanced stage because most of the symptoms are nonspecific; hence, the difficulty in diagnosis at early stages. More than 60% of women presenting with ovarian cancer have Stage III or IV cancer when metastasis is already present, with 5-year relative survival of just 27% [3] . Only 15% of women present when the malignancy is still localized, with a 5-year relative survival of 92% [3] .
Ovarian tumors present with a variety of symptoms, including abdominal pain, abdominal or adnexal mass, bloating, urinary urgency, and abnormal vaginal bleeding. Such clinical presentation could be caused by a number of different benign and malignant conditions. As a result, it usually poses a challenge to the gynecologist to distinguish between benign and malignant tumors. Consequently, there has been vigorous research into ovarian cancer screening methods and diagnostic tools. In 1990, Jacobs et al [4] developed the risk of malignancy index (RMI) after assessing how age, ultrasound score, menopausal status, clinical impression score, and serum CA-125 level could best distinguish between patients with benign and malignant pelvic masses. They noted that each criterion used alone provided statistically significant discrimination, with the most useful individual criteria being serum CA-125 level of 30 U/mL (sensitivity 81%, specificity 75%) and an ultrasound score of 2 (sensitivity 71%, specificity 83%) [4] . Jacobs et al therefore proposed that the combination of three criteria in an RMI is an effective tool to distinguish between cancer and benign lesions and is calculated using the product of the serum CA-125 level (U/mL), the ultrasound result (expressed as a score of 0, 1, or 3) and the menopausal status (1 if premenopausal and 3 if postmenopausal). By using an RMI cutoff level of 200, the sensitivity was 85% whereas the specificity was 97%, and patients with an RMI score of more than 200 had, on average, 42 times the background risk of cancer compared to 0.15 times the background risk in those with a lower score [4] . Tingulstad et al [5, 6] developed modified RMI in 1996 (RMI 2) and 1999 (RMI 3), with differences mainly in scorings of ultrasound findings and menopausal status.
Although the Guideline Development Group of the National Institute for Health and Clinical Excellence (NICE) suggested that RMI 1 was the most useful index at identifying women with ovarian cancer compared to other malignancy indices in secondary care, it noted that current evidence did not indicate the optimum cutoff score to use for guiding management [7] . It therefore recommended that further research should be undertaken to determine the optimum threshold for RMI 1 that should be applied in secondary care to guide the management of women with suspected ovarian malignancy [7] .
The purpose of this study is to evaluate the accuracy of the RMI, which combines serum CA-125 levels, ultrasound score, and menopausal state, in distinguishing between benign and malignant pelvic masses in the Welsh population. Although studies have validated the RMI in various populations [8e15], none has been done in Wales. This study is also aimed at determining the optimum threshold for the three RMIs. The long-term aim is to have a unified risk scoring system across Wales.
Materials and methods
The Abertawe Bro Morgannwg University Health Board is one of the largest health boards in Wales serving a population of approximately 600,000 covering the areas of Bridgend, Neath Port Talbot, and Swansea in South West Wales, United Kingdom. The Gynaecology Multidisciplinary Team (MDT) is based at the Singleton Hospital in Swansea, which is a 550-bed district general hospital. In addition to patients from Singleton Hospital, the Gynaecology MDT also discusses patients referred from seven other National Health Service (NHS) hospitals and many private clinics.
The Trust's database was used to identify women who had been referred to the gynecological oncology unit for management of pelvic mass and were discussed at the Multidisciplinary Meeting (MDM) over an 18-month period between January 2010 and June 2011. A total of 328 patients were identified in the database. Fifteen of the records were either incomplete or unavailable for review. Fifty-three of the remaining charts did not have an ultrasound examination and CA-125 was not recorded in six of the charts. Seven of the patients did not have both ultrasound examination and CA-125 recorded. Hence, a total of 247 patients were included in this retrospective review.
Three versions of RMI were compared, each incorporated serum CA-125 level, menopausal status, and ultrasound findings (Table 1) . To calculate the RMI, the formula serum CA-125 x M x U is used. Serum CA-125 is the assayed level of the tumor marker expressed in kU/L, M refers to the menopausal status of the patient, and U is the ultrasound score.
In Singleton Hospital, CA-125 is considered normal if it is < 35 kU/L and it is commonly measured in women presenting with adnexal masses.
Ultrasound score is computed based on the presence or absence of five features e multiloculated cyst, evidence of solid areas, bilateral lesions, presence of ascites, and evidence of metastases. In RMI 1, U ¼ 0 if none of these features is present, 1 if one feature is present, and 3 if two or more features are present. For RMI 2, U ¼ 1 if none or one feature is present and 4 if two or more features are present. In RMI 3, U ¼ 1 if none or one feature is present and 3 if two or more features are present.
Surgical specimens are usually sent for histology and the results of patients included in this study were documented. In some cases where the lesion was considered benign from imaging review, resulting in no surgical intervention, the diagnosis was assumed to be correct (for example, ovarian cyst not otherwise specified).
The data were analyzed using PASW Statistics for Windows, Version 18.0 (SPSS Inc., Chicago). A p-value of < 0.05 was considered statistically significant using Pearson Chi-square test. A receiver operating characteristic (ROC) curve was produced to show the relation between sensitivity and specificity of the RMI in distinguishing between benign and malignant masses. The closer the ROC curve is to the upper left corner, the higher the overall accuracy of the test [16] .
Results
Two hundred forty-seven women with adnexal masses were included in this retrospective study with a mean age of 58.09 years (range 19e95 years). One hundred sixty of the women had benign masses, whereas 87 women had malignant masses, giving a ratio of 2:1. Eighty patients were premenopausal, of whom 59 had benign masses and 21 had malignant masses. The number of postmenopausal women was 167 and of these, 101 had benign lesions whereas 66 had malignant neoplasm. The average age of women with benign lesions was 56.96 ± 17.991 years [95% confidence interval (CI), 54.15e59.77] and the average age for women with malignant masses was 60.16 ± 15.6 years (95% CI, 56.84e63.49). Postmenopausal women have a higher incidence of both benign and malignant lesions (p ¼ 0.041). The 51e60 age group had the highest incidence of ovarian malignancy (n ¼ 23).
The presence of ascites on ultrasound examination was significantly associated with a higher possibility of malignant adnexal mass (p < 0.001). There was no association between parity and pelvic mass (p ¼ 0.748).
Of the 87 women in whom malignant masses were diagnosed, the International Federation of Gynecology and Obstetrics stage was not recorded in 13 malignancy was a Stage III disease, but the subgroup could not be determined.
Most of the benign ovarian lesions were unspecified ovarian cysts (n ¼ 106). Other benign lesions that were diagnosed include dermoid cyst (n ¼ 10), serous cystadenoma (n ¼ 8) and mature teratoma (n ¼ 7). The most common malignant histological diagnoses were serous cystadenocarcinoma and papillary serous cystadenocarcinoma (Table 2) . Statistically significant differences were recorded between the benign and malignant groups in the ultrasound score variable. Most of the women with two or more ultrasound abnormalities had malignant pathology (Table 3) .
The mean serum CA-125 level in the benign and malignant groups was 50.86 kU/L and 654.34 kU/L, respectively. The sensitivity and specificity of CA-125 at 35 kU/L was 76% and 67%, respectively (Table 4) . CA-125 was found to be a relevant predictor of malignancy with an area under the ROC curve of 0.81. However, the area under the ROC curve for each of the risk of malignancy indices was greater than the area for the CA-125 serum levels. The comparisons between the sensitivity and specificity of the RMI scores and the individual elements of the scoreeCA-125, menopausal status, and ultrasound scoreealso showed that the performance of the RMI was better than the individual elements.
The (Fig. 2) . Using a threshold of 200, RMI 1 had a sensitivity of 66% and a specificity of 91%; RMI 2 had a sensitivity of 74% and a specificity of 79%; and RMI 3 had a sensitivity of 68% and a specificity of 85% (Table 5 ). Using a RMI cutoff level of 250, the sensitivity of RMI 1 dropped to 60% while the specificity increased to 94%. The sensitivity of RMI 2 also dropped to 71% and the specificity was 84%. At a threshold of 250, RMI 3 also recorded a drop in sensitivity to 61% and the specificity increased to 90% (Table 5) . A lower threshold of 120 for RMI 1, however, revealed a sensitivity of 74% and specificity of 84%.
Discussion

Main findings
The aim of this study was to determine if the three versions of RMI, which combines serum CA-125 levels, ultrasound findings, and menopausal state, can distinguish between benign and malignant adnexal masses. The results of this study will facilitate more appropriate referrals to the specialized gynecological oncology centers across Wales and help in determining the necessity of surgery, resulting in appropriate care for women with gynecological malignancies and optimization of healthcare resources.
Many of the women in this study who had malignant pelvic masses were at Stage 1. The lower numbers in Stages 3 and 4 could be because most of the women at these stages would have presented with obvious symptoms of malignancy. Therefore, they would have had a CT rather than an ultrasound, which would make them ineligible for inclusion into this study.
Although the area under the ROC curve for each of the risk of malignancy indices was greater than the area for the CA-125 serum levels, CA-125 was still found to be a relevant predictor of malignancy. At 50 kU/L, 78% of malignant masses were detected. It would therefore not be unreasonable for general practitioners to refer women with CA-125 levels above 50 kU/L to the secondary health centers. This study demonstrates the ability of RMI to correctly identify benign and malignant adnexal masses. It shows the high specificity of all the three risk of malignancy indices at an optimal cutoff of 200. The specificities for RMI 1, RMI 2, and RMI 3 were 91%, 79%, and 85% respectively, which is similar to previous studies [17, 18] . A high specificity is important because it reduces the number of surgical procedures performed for benign cases in tertiary gynecological oncology centers, therefore optimizing resources for patients with malignant pelvic masses. Using a cutoff of 200, the preoperative RMI had a sensitivity of 66%, 74%, and 68% for RMI 1, RMI 2, and RMI 3, respectively.
The RMI 3 is a modified version of the RMI 1, which was proposed by Tingulstad et al [6] . In their study, they observed that sensitivity and specificity to malignancy were 71% and 92% respectively when a cutoff of 200 was used [6] . In this study, when a cutoff of 200 was used for RMI 3, the sensitivity and specificity were 68% and 85%, respectively, which were comparable to Tingulstad et al's results.
Some studies have found that RMI 2 is more reliable in preoperative evaluation of women with pelvic masses [5, 19, 20] . However, in this study, the performance of the malignancy indices varied depending on the threshold used.
The optimal threshold for each of the three RMIs varied, although many studies used a cutoff of 200 for the three RMIs [5, 8, 19, 21] . For RMI 1, the optimal threshold is 120 with a sensitivity of 74% and specificity of 84%. For RMI 2, it was 200 with a sensitivity and specificity of 74% and 79%, respectively. The balance was achieved at a threshold of 150 for RMI 3 with a sensitivity of 74% and specificity of 80%. The lower cutoff for RMI 1 is probably because an ultrasound score of 0 is assigned when none of the ultrasound features are present, resulting in an RMI of 0 regardless of the serum CA-125 level and menopausal status. However, ultrasound results are heavily operator dependent and a sinister mass may be inadvertently reported as normal by an operator, resulting in a low RMI even when the CA-125, which is an important parameter of the RMI, is abnormal.
Had a cutoff of 200 been used for the three RMIs, six malignant cases identified by RMI 2 would have been missed using RMI 1. RMI 3 would have missed five malignant cases identified by RMI 2. The five malignant cases missed by both RMI 1 and 3 were two borderline mucinous cystadenoma, one high-grade papillary serous cystadenocarcinoma, one clear cell tumor, and one borderline serous cystadenoma. In addition, RMI 1 also missed one poorly differentiated serous cystadenocarcinoma. It is not surprising that some of the borderline tumors were missed because they tend to have lower RMI scores compared to invasive malignancies, hence they are less detectable. This is because borderline tumors exhibit different characteristics biochemically and morphologically from invasive malignancies and are therefore unlikely to be detected using tests designed primarily to detect invasive malignant diseases [22] .
The gynecological oncology MDT in Singleton Hospital currently uses RMI 1 based on NICE's recommendation. The MDT considers pelvic masses with an RMI 1 score < 25 as low risk, which should be managed locally, 25e250 as intermediate risk, which would be discussed at the MDT and managed locally if appropriate, and > 250 as high risk, which would require further investigation and immediate referral to a cancer center. Based on this study, a threshold of 250 has a sensitivity and specificity of 60% and 94%, respectively, for RMI 1. While noting that current evidence did not indicate the optimum cutoff to use for guiding management, NICE recommends a cutoff of 250 because it was thought that this would ensure access to specialist centers without overburdening them with benign disease and the associated additional costs [7] . This study shows that RMI 1 threshold of 250 has a high specificity indeed, although the sensitivity has been affected relative to the specificity. However, using a cutoff of 200, the sensitivity increased to 66% without any major loss of specificity (91%).
Strengths
This is the first study in Wales to validate the use of the risk of malignancy indices in the preoperative evaluation of women with pelvic masses in the Welsh population. With almost one-fifth of Wales' population in the region where this study was conducted, the local authority area's age and sex profile is very similar to that of Wales as a whole [23] . This study also has a large sample size Fig. 2 . Receiver operating characteristic (ROC) curves for CA-125 levels, RMI 1, RMI 2, and RMI 3 in the discrimination between benign and malignant adnexal masses. compared to similar previous studies in the literature, therefore making the findings of this study more reliable.
Limitations
A major limitation of this study is the retrospective design. A future prospective study is likely to have fewer potential sources of bias and confounding. Furthermore, because our center is a major referral center for South West Wales, it is likely that the percentage of malignant lesions in this study is higher than in peripheral hospitals where a larger proportion of women would present with benign pelvic masses. In addition, we do not know the outcome of some of the patients considered to be low risk that we sent back to the peripheral hospitals for management. Such information could have affected our results.
Interpretation
The RMI is a simple scoring system that is easily applicable to daily clinical practice. It is important that every center in Wales adopts only one version of the RMIs in its evaluation of cases with its corresponding optimal cutoff so as to ensure consistency and to avoid confusion. It would also be suggested that each center evaluates the interobserver and intraobserver variations in ultrasound examinations of pelvic masses so as to ensure reproducibility and accuracy of consequent ultrasound scorings. The possibility of scoring from computed tomography scans should also be evaluated because many women with suspicious adnexal masses currently are evaluated with computed tomography in the absence of ultrasonography.
Conclusion
Practical recommendations
This is the first study in Wales to evaluate the accuracy of RMI 1, RMI 2, and RMI 3 in discriminating between benign and malignant pelvic masses in the Welsh population. RMI is a simple and cheap scoring system that should be adopted across Wales in referring patients to the specialist cancer centers, especially because of our wide geographical area and low population density. According to the ROC curve, RMI 1 and RMI 2 performed better than RMI 3 in triaging women with pelvic masses. RMI 2 performed better than RMI 1 and RMI 3 at the cutoff of 200, which is comparable to published studies, but overall RMI 1 appears to be the best predictor.
It should be noted that RMI is only a guide; therefore, patients with a family history of ovarian and/or breast cancer and those with past medical history of breast and reproductive tract malignancy should be further evaluated even when their RMI score is low.
Research recommendations
At a cutoff of 200, RMI 2 was the most sensitive, although less specific than RMI 1 and RMI 3. Overall, RMI 1 and RMI 2 are better malignancy predictors than RMI 3. It is therefore suggested that both RMI 1 and RMI 2 be compared in a head-to-head prospective study, although we suspect that RMI 1 is likely to be the overall best malignancy predictor.
